CEPI – Coalition for Epidemic Preparedness Innovations  [to 15 July 2017]
08 July 2017
Norway strengthens its commitment to CEPI
CEPI welcomes global leadership shown by government of Norway
CEPI welcomes the vital contribution of additional funding from the government of Norway, which today announced it is increasing its original investment in CEPI by $70m. The government of Norway is a founding investor in CEPI, which will create new vaccines against epidemic threats through an innovative partnership between public, private, philanthropic and civil organizations.
Together with the governments of Germany and Japan, the Bill & Melinda Gates Foundation and Wellcome, the founding investors contributed a total of $540m to launch CEPI in January 2017. CEPI’s mission is to outsmart epidemics by developing safe and effective vaccines against known infectious diseases that can be deployed rapidly to contain outbreaks, before they become global health emergencies.
Responding to the announcement by the Prime Minister of Norway, Erna Solberg, at the G20 summit, Richard Hatchett, CEO of CEPI said:
“Norway was at the forefront of the world’s response to Ebola. Its far-sightedness helped facilitate the clinical evaluation of an Ebola vaccine that showed 100% effectiveness. It demonstrated that same spirit when it became a founding investor in CEPI. And today, we thank the government of Norway for this additional vital investment. This is a wonderful example of global leadership that will strengthen our defenses against the diseases that threaten the health, prosperity and security of us all. It is further proof of the momentum within the G20 to support collective action against future epidemics.”…

The Vaccine Confidence Project  [to 15 July 2017]
12 Jul, 2017
EU judgment on vaccine claims: Vaccine confidence breaker or trust builder?
Confidence Commentary – Heidi Larson With Shalini Anand reporting from India
A recent landmark judgment by the European Court of Justice (ECJ) has shaken the global health community. Scientists from all over the world have voiced dissent, as the ruling threatens to undermine science-based evidence and impact on vaccine confidence….
NIH  [to 15 July 2017]
July 13, 2017
Experimental Zika virus vaccines restrict in utero virus transmission in mice
— Vaccines protect against Zika-related congenital damage.

July 12, 2017
HIV hijacks surface molecule to invade cell
— NIH discovery could lead to new drugs to prevent HIV infection.

July 10, 2017
NIH launches prospective study of Zika and HIV co-infection during pregnancy
— Study to determine potential risks that infection with Zika may pose for pregnancies in which the mother is also has HIV.
UNAIDS  [to 15 July 2017]
Selected Press Releases & Updates
Review of Global Commission on HIV and the Law identifies progress and challenges
“Laws that criminalize HIV are anti-science, unjust and unconstructive”
14 July 2017
Five years ago, a landmark report published by the Global Commission on HIV and the Law urged governments to promote laws and policies grounded in evidence and human rights in order to turn the tide against AIDS. On 12 and 13 July, members of the commission and other experts came together to assess the progress made in advancing the report’s recommendations, look at the barriers that remain and discuss opportunities for further progress.
The participants recognized the role of the commission as a catalyst for social justice and human rights in the HIV response. Since the release of the commission’s report in 2012, efforts to advance the report’s recommendations have been documented in 88 countries. Several countries have conducted comprehensive assessments of laws, policies and practices affecting people living with HIV and have changed legislation as a result. National conversations on the rights of people living with and vulnerable to HIV have led countries to reform discriminatory practices against people living with HIV. Judges, civil society organizations and partners have been instrumental in helping to overturn discriminatory legislation and counter HIV stigma…

European Medicines Agency  [to 15 July 2017]
Call for independent scientific experts to join EMA’s Pharmacovigilance Risk Assessment Committee (PRAC)
Expressions of interest to be submitted to European Commission by 30 September 2017
Wellcome Trust  [to 15 July 2017]
11 July 2017
Researchers establish key mechanism controlling cell division
Researchers at the Francis Crick and Gurdon Institutes have pinpointed the mechanism that activates a key point in embryonic development. This could help scientists develop new treatments for diseases where the cell cycle is disrupted, such as cancer.
Industry Watch
:: Sanofi to acquire Protein Sciences 
Acquisition adds recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio
Paris, France – July 11, 2017 – Sanofi announced today it will acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, Connecticut in the United States. Under the terms of the agreement, Sanofi will make an upfront payment of $650 million and pay up to $100 million upon achievement of certain milestones.
Protein Sciences received approval from the US Food and Drug Administration (FDA) in October 2016 for their Flublok® Quadrivalent Influenza Vaccine (QIV). Flublok® is the only recombinant protein-based influenza vaccine approved by the FDA.
“The acquisition of Protein Sciences will allow us to broaden our flu portfolio with the addition of a non-egg based vaccine,” said David Loew, Sanofi Executive Vice President and Head of Sanofi Pasteur, Sanofi’s vaccines division.
“Protein Sciences was actively looking for an opportunity to grow its business, particularly in the US,” said Manon M.J. Cox, President and Chief Executive Officer, Protein Sciences. “As part of Sanofi Pasteur, we expect our Flublok influenza vaccine to benefit from Sanofi Pasteur’s expertise in the field of influenza vaccines.”
The acquisition, which has been unanimously approved by the board of directors of Protein Sciences and a majority of Protein Sciences shareholders, is expected to close in the third quarter of 2017, subject to customary regulatory approvals.


BIO    [to 15 July 2017]
Jul 13 2017
Jennifer Dent (BIO Ventures for Global Health) at the 2017 BIO International Convention
Mike Huckman interviews Jennifer Dent (BIO Ventures for Global Health) at the 2017 BIO International Convention Buzz Center

Jul 13 2017
Nima Farzan (PaxVax) at the 2017 BIO International Convention
Mike Huckman interviews Nima Farzan (PaxVax) at the 2017 BIO International Convention Buzz Center.

PhRMA    [to 15 July 2017]
July 12, 2017
PhRMA Statement on House Passage of PDUFA VI Reauthorization
PhRMA president and CEO Stephen J. Ubl issued the following statement on the House passage of PDUFA reauthorization.

July 12, 2017
New “Let’s Talk About Cost” campaign convenes national dialogue on medicine costs
Discussions about costs are important. We recognize that many are struggling to access their medicine and have important questions about their medicine costs.